Array Biopharma Inc  

(Public, NASDAQ:ARRY)   Watch this stock  
Find more results for ARRY
18.15
+0.26 (1.45%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.31 - 18.30
52 week 6.73 - 18.30
Open 17.92
Vol / Avg. 2.59M/4.86M
Mkt cap 3.58B
P/E     -
Div/yield     -
EPS -0.77
Shares 207.64M
Beta 2.03
Inst. own 100%
May 8, 2018
Q3 2018 Array Biopharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 12, 2018
Array Biopharma Inc at Cowen Health care Conference - 3:30PM EDT - Add to calendar
Feb 14, 2018
Array Biopharma Inc at Leerink Partners Global Healthcare Conference
Feb 6, 2018
Q2 2018 Array Biopharma Inc Earnings Release
Feb 6, 2018
Q2 2018 Array Biopharma Inc Earnings Call - Webcast
Jan 8, 2018
Array Biopharma Inc at JPMorgan Healthcare Conference - Webcast
Nov 29, 2017
Array Biopharma Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -80.66% -77.44%
Operating margin -76.21% -68.66%
EBITD margin - -66.30%
Return on average assets -28.30% -52.15%
Return on average equity -58.27% -
Employees 209 -
CDP Score - -

Address

3200 Walnut St
BOULDER, CO 80301-2514
United States - Map
+1-303-3816600 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

Officers and directors

Kyle A. Lefkoff Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ron R. Squarer Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Jason Haddock Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Andrew R. Robbins Chief Operating Officer
Age: 41
Bio & Compensation  - Reuters
Nicholas A. Saccomano Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Curtis Gale Oltmans General Counsel
Age: 54
Bio & Compensation  - Reuters
Victor Sandor Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Shalini Sharp Director
Age: 42
Bio & Compensation  - Reuters
Charles M. Baum M.D., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters